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The Use of Histamine in Cancer Immunotherapy
To the Editor:
We read with interest the article by Hegyesi et al (2001) that reports
on the expression of histidine decarboxylase (HDC) in human
melanoma cells in vivo by western blotting and immunostaining on
tissue specimens from patients with primary melanoma (n = 20),
melanoma metastases (n = 5), nevi (n = 3), and normal skin
(n = 10). Furthermore, the report demonstrated that a HDC-
speci®c antisense oligonucleotide (ASO) suppressed melanoma cell
proliferation in two cell lines in vitro compared with a nonsense 18-
mer ASO. The authors speculate that endogenous histamine may
act as an autocrine growth factor, in¯uencing cell proliferation via
H2 histamine receptors (Burtin et al, 1988; Bolton et al, 2000), or
that melanoma growth is indirectly favored by locally produced
histamine that suppresses IFN-g production of surrounding
immune cells and therefore contributes to immune escape of
melanoma cells. Consequently, the authors argue, not only
traditional antihistaminics such as H2 histamine antagonists but
also ASO targeting HDC may soon became candidates for use in
melanoma treatment.
As some experimental ®ndings as well as current clinical
strategies are completely opposed, we would like to comment on
some of the reported statements of Hegyesi et al (2001).
First of all, we believe that the methodology employed to
determine HDC (e.g., western blot) is not adequate to draw any
®rm conclusions as it is long known that many tumors, including
melanoma, are surrounded by signi®cantly larger numbers of mast
cells containing histamine and HDC compared with nevi and
normal skin (Schadendorf et al, 1995). Furthermore, mast cell
counts are highly dependent on anatomical sites (Eady et al, 1979;
Cowen et al, 1979). Neither anatomical location nor the number of
mast cells is taken into account when tissues specimens are analyzed
by western blotting, thus leading to false hypotheses. Nevertheless,
the suppression of melanoma cell proliferation in two cell lines
in vitro is convincing. It cannot, however, be ruled out that other
genes critically involved in proliferation are affected which also
contribute to growth retardation. Our own data demonstrate that
histamine within a concentration range of 1±1000 mM had no
in¯uence on melanoma cell proliferation in vitro (D.S. and C.S.,
unpublished results).
Instead of using antihistamines (as was suggested by these
authors), histamine was introduced into the treatment of patients
with metastatic melanoma with some success in combination with
interleukin-2 (IL-2) (Hellstrand et al, 1994, 2000; Hauschild et al,
2001; Agarwala et al, 2002). Although the exact basis of action is
presently unclear, preclinical data suggest that histamine protects T
cells and natural killer cells against oxidative stress (Hansson et al,
1999) and leads to synergistic activation of lymphocytes in vitro.
Furthermore, histamine and IL-2 synergize in activating such
effects (Hellstrand et al, 2000). In pilot studies (Hellstrand et al,
1994, summarized in Hellstrand et al, 2000) as well as in a
prospective, randomized multicenter study (Agarwala et al, 2002), it
became clear that histamine dihydrochloride (Ceplene; previously
known as Maxamine) exhibits unexpected clinical bene®ts in
patients with metastatic melanoma of the liver (Hauschild et al,
2001; Agarwala et al, 2002), thus achieving for the ®rst time
signi®cant survival advantage for metastatic melanoma patients
using a combination of histamine and IL-2 in comparison with
patients treated with IL-2 only.
In conclusion, as histamine and HDC have been detected in
other cells besides melanoma cells, differentiating analytical
methods have to be chosen appropriately. Conclusion and
suggestions regarding possible clinical bene®ts have to be drawn
with utmost caution. Whether histamine dihydrochloride in
combination with IL-2 is really of bene®t in a subset of melanoma
patients is currently being tested in a con®rmatory prospective,
randomized, international multicenter trial in patients with liver
metastases. Results can be expected in 2±3 y.
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Reply
To the Editor:
Earlier and recent data (cited by the letter of Dr. Schadendorf)
about the combined application of exogenously added histamine
and interleukin (IL) seem to indicate a promising approach in
melanoma therapy. The effect is likely based on an earlier view
(Hellstrand et al, 2001) that histamine suppresses the inhibitory
action of macrophages on natural killer cells.
Our and others' recent and earlier data suggest ®ve things:
1. Regardless of the sometimes debated presence of mast cells in
melanoma tissue, there is endogenous expression of histidine
decarboxylase (HDC) mRNA (thus presence of HDC is proved
not only by western blots, but also by HDC mRNA being
visualized by in situ hybridization) and immunoreactive histamine
within melanoma cells (Haak-Fredscho et al, 2000). This fact and
the amount of HDC is not in direct relation with poor prognosis of
melanoma; however, suppression of melanoma cell growth with
HDC-speci®c antisense oligonucleotides suggests that the involve-
ment of locally produced histamine is hardly questionable.
2. Histamine receptor (HR) 1 agonists directly decrease, whereas
HR2 agonists directly increase proliferation of melanoma cells
(Reynolds et al, 1996; Lazar-Molnar et al, submitted), thus actual
and local ratio between HR1 and HR2 on melanoma cells seems to
be critical for the net outcome of the action of endogenously
produced histamine.
3. HR2 antagonist cimetidine, particularly if combined with a
tamoxifen derivative N,N-diethyl-2-{4-phenylmethyl)phenoxy}-
ethanamine-HCl (DPPE) (Brandes et al, 1991), strongly decreases
tumor mass and increases survival of immunode®cient SCID xeno-
transplanted with human melanoma cell line (Szincsak et al, in
press).
4. There are abundant clinical data on the bene®cial effect of HR2
antagonists on carcinoma (Nielsen, 1996; Bolton et al, 2000).
5. Concerning the interactions with local immune response,
reciprocal inhibitory interactions are found between histamine
and interferon g (Horvath et al, 1999; Heninger et al, 2000).
Furthermore, histamine and locally produced IL-6 are mutually
stimulatory (Lazar-Molnar et al, 2000; Lazar-Molnar et al, submit-
ted). This fact further emphasizes the role of local histamine, as IL-6
(partially generated by the melanoma cells themselves) is also one of
the multiple growth factors for melanoma depending on the
metastatic potential of the tumor. Interestingly, IL-6 in¯uences the
local expression pattern of histamine receptors, this fact provides a
further factor in the autocrine and paracrine effect of histamine on
melanoma cells.
In conclusion, impressive data suggest that therapeutically
administered histamine potentiates the effect of IL-2, as an adjuvant
or by another, not yet discovered mechanism. Nevertheless, this is
not in controversy with our view that locally produced histamine
acting on paracrine or autocrine way in¯uence tumor growth on a
receptor (i.e., signal pathway)-dependent manner and endogen-
ously produced and acting histamine shifts local T cell response
toward Th2 polarization.
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